1. Home
  2. VERA vs GLPG Comparison

VERA vs GLPG Comparison

Compare VERA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERA
  • GLPG
  • Stock Information
  • Founded
  • VERA 2016
  • GLPG 1999
  • Country
  • VERA United States
  • GLPG Belgium
  • Employees
  • VERA N/A
  • GLPG N/A
  • Industry
  • VERA Biotechnology: Pharmaceutical Preparations
  • GLPG Biotechnology: Pharmaceutical Preparations
  • Sector
  • VERA Health Care
  • GLPG Health Care
  • Exchange
  • VERA Nasdaq
  • GLPG Nasdaq
  • Market Cap
  • VERA 2.0B
  • GLPG 1.8B
  • IPO Year
  • VERA 2021
  • GLPG 2005
  • Fundamental
  • Price
  • VERA $20.86
  • GLPG $27.42
  • Analyst Decision
  • VERA Buy
  • GLPG Sell
  • Analyst Count
  • VERA 8
  • GLPG 4
  • Target Price
  • VERA $64.63
  • GLPG $25.33
  • AVG Volume (30 Days)
  • VERA 2.9M
  • GLPG 271.5K
  • Earning Date
  • VERA 08-07-2025
  • GLPG 07-23-2025
  • Dividend Yield
  • VERA N/A
  • GLPG N/A
  • EPS Growth
  • VERA N/A
  • GLPG N/A
  • EPS
  • VERA N/A
  • GLPG N/A
  • Revenue
  • VERA N/A
  • GLPG $311,493,731.00
  • Revenue This Year
  • VERA N/A
  • GLPG $0.78
  • Revenue Next Year
  • VERA N/A
  • GLPG N/A
  • P/E Ratio
  • VERA N/A
  • GLPG N/A
  • Revenue Growth
  • VERA N/A
  • GLPG 18.32
  • 52 Week Low
  • VERA $18.53
  • GLPG $22.36
  • 52 Week High
  • VERA $51.61
  • GLPG $31.23
  • Technical
  • Relative Strength Index (RSI)
  • VERA 43.65
  • GLPG 44.30
  • Support Level
  • VERA $20.37
  • GLPG $27.67
  • Resistance Level
  • VERA $23.14
  • GLPG $29.28
  • Average True Range (ATR)
  • VERA 1.70
  • GLPG 0.57
  • MACD
  • VERA -0.46
  • GLPG -0.19
  • Stochastic Oscillator
  • VERA 3.88
  • GLPG 13.10

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Share on Social Networks: